S. Michael Rothenberg

Chief Medical Officer


Denver, CO


College: Yale University (B.A. Chemistry) MD-PhD Stanford (advisor Pat Brown); Residency Internal Medicine Massachusetts General Hospital Fellowship Oncology Dana Farber Cancer Institute-Massachusetts General Hospital

Other insitrocytes Describe Me As

Devoted to making clinical trials more effective; objective and data-driven; authentic.

As chief medical officer, Mike leads all aspects of clinical development, including strategy on clinical trial design; oversees medical affairs, pharmacovigilance and regulatory affairs; and drives translational biology. Mike is a trained oncologist who brings two decades of clinical care and drug development experience spanning target identification through approval. He has worked across multiple therapeutic modalities, including small molecules, antibodies, antibody drug conjugates, bispecific engagers, and novel protein-engineered therapeutics, making significant contributions to many first- and best-in-class medicines.

Prior to insitro, he was vice president of early oncology development and clinical research at Pfizer, where he oversaw Pfizer’s oncology and hematology early clinical development portfolio, advancing more than 20 first-in-patient clinical trials, including supervising elranatamab (Elrexfio™, a CD3-targeting bispecific antibody) through the first-in-human trial to human proof-of-concept. Prior to Pfizer, he was vice president of research and development at Loxo Oncology, where he led early clinical development for novel, targeted anticancer therapies, including the approved RET inhibitor RETEVMO® (selpercatinib) from seamless clinical trial design and protocol authoring through trial oversight and New Drug Application. He previously served as a medical oncologist and researcher focused on targeted therapeutics at Massachusetts General Hospital.

Key Papers:

SHP2 Inhibition Sensitizes Diverse Oncogene- Addicted Solid Tumors to Re-treatment with Targeted Therapy

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

A next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors